181 related articles for article (PubMed ID: 12230626)
1. Vitamin D receptor-dependent antitumour effects of 1,25-dihydroxyvitamin D3 and two synthetic analogues in three in vivo models of prostate cancer.
Oades GM; Dredge K; Kirby RS; Colston KW
BJU Int; 2002 Oct; 90(6):607-16. PubMed ID: 12230626
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of vitamin D analogs as therapeutic agents for prostate cancer.
Chen TC; Holick MF; Lokeshwar BL; Burnstein KL; Schwartz GG
Recent Results Cancer Res; 2003; 164():273-88. PubMed ID: 12899529
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089.
Lokeshwar BL; Schwartz GG; Selzer MG; Burnstein KL; Zhuang SH; Block NL; Binderup L
Cancer Epidemiol Biomarkers Prev; 1999 Mar; 8(3):241-8. PubMed ID: 10090302
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system.
Getzenberg RH; Light BW; Lapco PE; Konety BR; Nangia AK; Acierno JS; Dhir R; Shurin Z; Day RS; Trump DL; Johnson CS
Urology; 1997 Dec; 50(6):999-1006. PubMed ID: 9426741
[TBL] [Abstract][Full Text] [Related]
5. A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice.
Blutt SE; Polek TC; Stewart LV; Kattan MW; Weigel NL
Cancer Res; 2000 Feb; 60(4):779-82. PubMed ID: 10706079
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D-induced up-regulation of tumour necrosis factor alpha (TNF-alpha) in prostate cancer cells.
Golovko O; Nazarova N; Tuohimaa P
Life Sci; 2005 Jun; 77(5):562-77. PubMed ID: 15904673
[TBL] [Abstract][Full Text] [Related]
7. Sensitive induction of apoptosis in breast cancer cells by a novel 1,25-dihydroxyvitamin D3 analogue shows relation to promoter selectivity.
Danielsson C; Mathiasen IS; James SY; Nayeri S; Bretting C; Hansen CM; Colston KW; Carlberg C
J Cell Biochem; 1997 Sep; 66(4):552-62. PubMed ID: 9282333
[TBL] [Abstract][Full Text] [Related]
8. EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells.
Bhatia V; Saini MK; Shen X; Bi LX; Qiu S; Weigel NL; Falzon M
Mol Cancer Ther; 2009 Jul; 8(7):1787-98. PubMed ID: 19584236
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy.
Díaz GD; Paraskeva C; Thomas MG; Binderup L; Hague A
Cancer Res; 2000 Apr; 60(8):2304-12. PubMed ID: 10786699
[TBL] [Abstract][Full Text] [Related]
10. Action of low calcemic 1alpha,25-dihydroxyvitamin D3 analogue EB1089 in head and neck squamous cell carcinoma.
Prudencio J; Akutsu N; Benlimame N; Wang T; Bastien Y; Lin R; Black MJ; Alaoui-Jamali MA; White JH
J Natl Cancer Inst; 2001 May; 93(10):745-53. PubMed ID: 11353784
[TBL] [Abstract][Full Text] [Related]
11. 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo.
Schwartz GG; Hill CC; Oeler TA; Becich MJ; Bahnson RR
Urology; 1995 Sep; 46(3):365-9. PubMed ID: 7660511
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D receptor-dependent inhibition of mammary tumor growth by EB1089 and ultraviolet radiation in vivo.
Valrance ME; Brunet AH; Welsh J
Endocrinology; 2007 Oct; 148(10):4887-94. PubMed ID: 17628009
[TBL] [Abstract][Full Text] [Related]
13. Novel nonsecosteroidal vitamin D receptor modulator inhibits the growth of LNCaP xenograft tumors in athymic mice without increased serum calcium.
Polek TC; Murthy S; Blutt SE; Boehm MF; Zou A; Weigel NL; Allegretto EA
Prostate; 2001 Nov; 49(3):224-33. PubMed ID: 11746268
[TBL] [Abstract][Full Text] [Related]
14. RRR-alpha-vitamin E succinate potentiates the antitumor effect of calcitriol in prostate cancer without overt side effects.
Yin Y; Ni J; Chen M; Guo Y; Yeh S
Clin Cancer Res; 2009 Jan; 15(1):190-200. PubMed ID: 19118046
[TBL] [Abstract][Full Text] [Related]
15. Effects of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] and its analogues (EB1089 and analog V) on canine adenocarcinoma (CAC-8) in nude mice.
Kunakornsawat S; Rosol TJ; Capen CC; Reddy GS; Binderup L; Inpanbutr N
Biol Pharm Bull; 2002 May; 25(5):642-7. PubMed ID: 12033506
[TBL] [Abstract][Full Text] [Related]
16. Characterization of mammary tumor cell lines from wild type and vitamin D3 receptor knockout mice.
Zinser GM; McEleney K; Welsh J
Mol Cell Endocrinol; 2003 Feb; 200(1-2):67-80. PubMed ID: 12644300
[TBL] [Abstract][Full Text] [Related]
17. Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells.
James SY; Mackay AG; Colston KW
J Steroid Biochem Mol Biol; 1996 Jul; 58(4):395-401. PubMed ID: 8903423
[TBL] [Abstract][Full Text] [Related]
18. EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro.
Colston KW; Mackay AG; James SY; Binderup L; Chander S; Coombes RC
Biochem Pharmacol; 1992 Dec; 44(12):2273-80. PubMed ID: 1472092
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D receptor and p21/WAF1 are targets of genistein and 1,25-dihydroxyvitamin D3 in human prostate cancer cells.
Rao A; Coan A; Welsh JE; Barclay WW; Koumenis C; Cramer SD
Cancer Res; 2004 Mar; 64(6):2143-7. PubMed ID: 15026355
[TBL] [Abstract][Full Text] [Related]
20. Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog, EB1089.
VanWeelden K; Flanagan L; Binderup L; Tenniswood M; Welsh J
Endocrinology; 1998 Apr; 139(4):2102-10. PubMed ID: 9528999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
